FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968608370> ?p ?o ?g. }

• W2968608370 endingPage "563" @default.
• W2968608370 startingPage "563" @default.
• W2968608370 abstract "2402 The type I and type II topoisomerases are essential enzymes involved in altering DNA topology for the processing of genetic material. In humans the type II enzymes consist of two highly homologous isozymes, topoisomerase (topo) IIα and topo IIβ of molecular weight 170 and 180 kDa, respectively. The interaction of these enzymes with DNA, make them important targets for cancer therapeutic agents. In vitro the topo IIα and β isoforms catalyze similar enzymatic reactions and do not differ in their ability to form a stable DNA cleavable complex with topo II targeting drugs. However, tumor models expressing different levels of topo IIα or topo IIβ following selection for resistance to specific topo II inhibitors are reported to differ in their response to clinically active topo II targeting drugs. In this study we used an isogenic model system, in which the topo IIα or the topo IIβ proteins were selectively down-regulated by stable transfection of the respective siRNAs in human leukemia HL-60 cells, to determine whether different topo II inhibitors target distinct topo II isoforms. The siRNA targeting topo IIα (sitopo IIα ) and topo IIβ (sitopo IIβ ) cloned into a pBabe vector led to a >20-fold and >30-fold stable down-regulation of the respective protein in HL-60 cells. A control transfection with green fluorescent protein (GFP) siRNA (siGFP) was also carried out. Comparison of drug-stabilized topo II-DNA cleavable complex (DNA-CC) formation in the siRNA transfected cells revealed that etoposide and amsacrine induced significantly (p=0.05) lower DNA-CC in cells transfected with sitopo IIα and sitopo IIβ , respectively as compared to those transfected with siGFP. In contrast, DNA-CC with camptothecin, a topo I-targeting drug, did not differ in these cells (p=0.30). Determination of drug induced cytotoxicity, measured by the soft-agar colony assay, revealed that sensitivity to etoposide was significantly (p=0.002) lower only in sitopo IIα transfected cells as compared to sitopo IIβ and siGFP transfected cells. In contrast, sensitivity to amsacrine and mitoxantrone, but not doxorubicin, was significantly (p=0.001) lower in sitopo IIβ transfected cells as compared to sitopo IIα and siGFP transfected cells. Induction of apoptosis by mitoxantrone was also attenuated only in sitopo IIβ transfected cells. These results suggest that the DNA damaging and down-stream cytotoxic effects of etoposide are dependent on adequate expression of topo IIα protein levels. In contrast, the anti-tumor effects of amsacrine and mitoxantrone are dependent on adequate expression of topo IIβ . Model systems with targeted down-regulation of topo II isoforms could be useful for testing novel topo II inhibitors. Further, profiling of patient tumors for differential expression of the topo II isozymes, α and β , could be a useful strategy to improve anti-tumor activity of clinically active topo II targeting drugs." @default.
• W2968608370 created "2019-08-22" @default.
• W2968608370 creator A5003423276 @default.
• W2968608370 creator A5007892424 @default.
• W2968608370 creator A5011692983 @default.
• W2968608370 creator A5022167065 @default.
• W2968608370 creator A5045171753 @default.
• W2968608370 creator A5062856275 @default.
• W2968608370 creator A5063166319 @default.
• W2968608370 creator A5069808553 @default.
• W2968608370 creator A5082466279 @default.
• W2968608370 date "2005-05-01" @default.
• W2968608370 modified "2023-09-24" @default.
• W2968608370 title "Targeted si-RNA mediated down-regulation of topoisomerase II α or β isozymes defines selectivity to inhibitors of the enzyme" @default.
• W2968608370 hasPublicationYear "2005" @default.
• W2968608370 type Work @default.
• W2968608370 sameAs 2968608370 @default.
• W2968608370 citedByCount "0" @default.
• W2968608370 crossrefType "journal-article" @default.
• W2968608370 hasAuthorship W2968608370A5003423276 @default.
• W2968608370 hasAuthorship W2968608370A5007892424 @default.
• W2968608370 hasAuthorship W2968608370A5011692983 @default.
• W2968608370 hasAuthorship W2968608370A5022167065 @default.
• W2968608370 hasAuthorship W2968608370A5045171753 @default.
• W2968608370 hasAuthorship W2968608370A5062856275 @default.
• W2968608370 hasAuthorship W2968608370A5063166319 @default.
• W2968608370 hasAuthorship W2968608370A5069808553 @default.
• W2968608370 hasAuthorship W2968608370A5082466279 @default.
• W2968608370 hasConcept C104317684 @default.
• W2968608370 hasConcept C119795356 @default.
• W2968608370 hasConcept C147897179 @default.
• W2968608370 hasConcept C153911025 @default.
• W2968608370 hasConcept C181199279 @default.
• W2968608370 hasConcept C185592680 @default.
• W2968608370 hasConcept C22615655 @default.
• W2968608370 hasConcept C2776694085 @default.
• W2968608370 hasConcept C2778119113 @default.
• W2968608370 hasConcept C2780500152 @default.
• W2968608370 hasConcept C54009773 @default.
• W2968608370 hasConcept C54355233 @default.
• W2968608370 hasConcept C552990157 @default.
• W2968608370 hasConcept C55493867 @default.
• W2968608370 hasConcept C86803240 @default.
• W2968608370 hasConceptScore W2968608370C104317684 @default.
• W2968608370 hasConceptScore W2968608370C119795356 @default.
• W2968608370 hasConceptScore W2968608370C147897179 @default.
• W2968608370 hasConceptScore W2968608370C153911025 @default.
• W2968608370 hasConceptScore W2968608370C181199279 @default.
• W2968608370 hasConceptScore W2968608370C185592680 @default.
• W2968608370 hasConceptScore W2968608370C22615655 @default.
• W2968608370 hasConceptScore W2968608370C2776694085 @default.
• W2968608370 hasConceptScore W2968608370C2778119113 @default.
• W2968608370 hasConceptScore W2968608370C2780500152 @default.
• W2968608370 hasConceptScore W2968608370C54009773 @default.
• W2968608370 hasConceptScore W2968608370C54355233 @default.
• W2968608370 hasConceptScore W2968608370C552990157 @default.
• W2968608370 hasConceptScore W2968608370C55493867 @default.
• W2968608370 hasConceptScore W2968608370C86803240 @default.
• W2968608370 hasLocation W29686083701 @default.
• W2968608370 hasOpenAccess W2968608370 @default.
• W2968608370 hasPrimaryLocation W29686083701 @default.
• W2968608370 hasRelatedWork W1969592907 @default.
• W2968608370 hasRelatedWork W1977764785 @default.
• W2968608370 hasRelatedWork W1984824591 @default.
• W2968608370 hasRelatedWork W200268486 @default.
• W2968608370 hasRelatedWork W2009436450 @default.
• W2968608370 hasRelatedWork W2017223073 @default.
• W2968608370 hasRelatedWork W2023573903 @default.
• W2968608370 hasRelatedWork W2042855463 @default.
• W2968608370 hasRelatedWork W2047486481 @default.
• W2968608370 hasRelatedWork W2079755465 @default.
• W2968608370 hasRelatedWork W2094220113 @default.
• W2968608370 hasRelatedWork W2151837692 @default.
• W2968608370 hasRelatedWork W2172262967 @default.
• W2968608370 hasRelatedWork W2185414837 @default.
• W2968608370 hasRelatedWork W2333640134 @default.
• W2968608370 hasRelatedWork W2539069462 @default.
• W2968608370 hasRelatedWork W2559130451 @default.
• W2968608370 hasRelatedWork W2770742561 @default.
• W2968608370 hasRelatedWork W2928494776 @default.
• W2968608370 hasRelatedWork W334816022 @default.
• W2968608370 hasVolume "65" @default.
• W2968608370 isParatext "false" @default.
• W2968608370 isRetracted "false" @default.
• W2968608370 magId "2968608370" @default.
• W2968608370 workType "article" @default.